Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer

D. Kurfurstova, J. Bartkova, R. Vrtel, A. Mickova, A. Burdova, D. Majera, M. Mistrik, M. Kral, FR. Santer, J. Bouchal, J. Bartek,

. 2016 ; 10 (6) : 879-894. [pub] 20160303

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc18017327

Grant support
NT13573 MZ0 CEP Register

The DNA damage checkpoints provide an anti-cancer barrier in diverse tumour types, however this concept has remained unexplored in prostate cancer (CaP). Furthermore, targeting DNA repair defects by PARP1 inhibitors (PARPi) as a cancer treatment strategy is emerging yet requires suitable predictive biomarkers. To address these issues, we performed immunohistochemical analysis of multiple markers of DNA damage signalling, oxidative stress, DNA repair and cell cycle control pathways during progression of human prostate disease from benign hyperplasia, through intraepithelial neoplasia to CaP, complemented by genetic analyses of TMPRSS2-ERG rearrangement and NQO1, an anti-oxidant factor and p53 protector. The DNA damage checkpoint barrier (γH2AX, pATM, p53) mechanism was activated during CaP tumorigenesis, albeit less and with delayed culmination compared to other cancers, possibly reflecting lower replication stress (slow proliferation despite cases of Rb loss and cyclin D1 overexpression) and progressive loss of ATM activator NKX3.1. Oxidative stress (8-oxoguanine lesions) and NQO1 increased during disease progression. NQO1 genotypes of 390 men did not indicate predisposition to CaP, yet loss of NQO1 in CaP suggested potential progression-opposing tumour suppressor role. TMPRSS2-ERG rearrangement and PTEN loss, events sensitizing to PARPi, occurred frequently along with heterogeneous loss of DNA repair factors 53BP1, JMJD1C and Rev7 (all studied here for the first time in CaP) whose defects may cause resistance to PARPi. Overall, our results reveal an unorthodox DNA damage checkpoint barrier scenario in CaP tumorigenesis, and provide novel insights into oxidative stress and DNA repair, with implications for biomarker guidance of future targeted therapy of CaP.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18017327
003      
CZ-PrNML
005      
20191025142128.0
007      
ta
008      
180515s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.molonc.2016.02.005 $2 doi
035    __
$a (PubMed)26987799
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kurfürstová, Daniela $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. $7 xx0269558
245    10
$a DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer / $c D. Kurfurstova, J. Bartkova, R. Vrtel, A. Mickova, A. Burdova, D. Majera, M. Mistrik, M. Kral, FR. Santer, J. Bouchal, J. Bartek,
520    9_
$a The DNA damage checkpoints provide an anti-cancer barrier in diverse tumour types, however this concept has remained unexplored in prostate cancer (CaP). Furthermore, targeting DNA repair defects by PARP1 inhibitors (PARPi) as a cancer treatment strategy is emerging yet requires suitable predictive biomarkers. To address these issues, we performed immunohistochemical analysis of multiple markers of DNA damage signalling, oxidative stress, DNA repair and cell cycle control pathways during progression of human prostate disease from benign hyperplasia, through intraepithelial neoplasia to CaP, complemented by genetic analyses of TMPRSS2-ERG rearrangement and NQO1, an anti-oxidant factor and p53 protector. The DNA damage checkpoint barrier (γH2AX, pATM, p53) mechanism was activated during CaP tumorigenesis, albeit less and with delayed culmination compared to other cancers, possibly reflecting lower replication stress (slow proliferation despite cases of Rb loss and cyclin D1 overexpression) and progressive loss of ATM activator NKX3.1. Oxidative stress (8-oxoguanine lesions) and NQO1 increased during disease progression. NQO1 genotypes of 390 men did not indicate predisposition to CaP, yet loss of NQO1 in CaP suggested potential progression-opposing tumour suppressor role. TMPRSS2-ERG rearrangement and PTEN loss, events sensitizing to PARPi, occurred frequently along with heterogeneous loss of DNA repair factors 53BP1, JMJD1C and Rev7 (all studied here for the first time in CaP) whose defects may cause resistance to PARPi. Overall, our results reveal an unorthodox DNA damage checkpoint barrier scenario in CaP tumorigenesis, and provide novel insights into oxidative stress and DNA repair, with implications for biomarker guidance of future targeted therapy of CaP.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a poškození DNA $7 D004249
650    _2
$a oprava DNA $7 D004260
650    _2
$a progrese nemoci $7 D018450
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a genotyp $7 D005838
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a NAD(P)H dehydrogenasa (chinon) $x analýza $x genetika $7 D016660
650    _2
$a fúzní onkogenní proteiny $x analýza $x genetika $7 D015514
650    12
$a oxidační stres $7 D018384
650    _2
$a fosfohydroláza PTEN $x analýza $x genetika $7 D051059
650    _2
$a prostata $x metabolismus $x patologie $7 D011467
650    _2
$a nádory prostaty $x genetika $x metabolismus $x patologie $7 D011471
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bártková, Jiřina $u Danish Cancer Society Research Center, Copenhagen, Denmark; Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden. Electronic address: jib@cancer.dk. $7 xx0094304
700    1_
$a Vrtěl, Radek $u Department of Medical Genetics, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic; Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. $7 xx0060360
700    1_
$a Mickova, Alena $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Burdova, Alena $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Majera, Dusana $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Mistrik, Martin $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Král, Milan $u Department of Urology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. $7 xx0079094
700    1_
$a Santer, Frederic R $u Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Austria.
700    1_
$a Bouchal, Jan, $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. Electronic address: jan.bouchal@upol.cz. $d 1973- $7 xx0034399
700    1_
$a Bártek, Jiří, $u Danish Cancer Society Research Center, Copenhagen, Denmark; Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden; Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. Electronic address: jb@cancer.dk. $d 1953- $7 xx0046271
773    0_
$w MED00167281 $t Molecular oncology $x 1878-0261 $g Roč. 10, č. 6 (2016), s. 879-894
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26987799 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20191025142604 $b ABA008
999    __
$a ok $b bmc $g 1300951 $s 1014167
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 10 $c 6 $d 879-894 $e 20160303 $i 1878-0261 $m Molecular oncology $n Mol Oncol $x MED00167281
GRA    __
$a NT13573 $p MZ0
LZP    __
$a Pubmed-20180515
Back

Find record

Citation metrics

Archiving options